Loading...
NASDAQ: NVIV
InVivo Therapeutics Holdings Corporation
Healthcare · Biotechnology
Market Cap
$995.92K
52w High
$2.40
52w Low
$0.22
P/E
-0.05
Volume
1.61M
Outstanding Shares
3.11M
Company profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI).
CEORichard M. Toselli
SectorHealthcare
IndustryBiotechnology
Employees6
IPO dateNov 15, 2010
Valuation
Forward P/E—
EV/EBITDA1.19
Enterprise value-$11.79M
Stock splits
Apr 27, 20221:25
Feb 12, 20201:30
Apr 17, 20181:25
Apr 8, 20151:4
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-64.64%▼18.38%vs FY2021
Analyst consensus
RatingBuy
Target price—
3
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Feb 14, 2024
View
EPS
Actual vs estimate by quarter
Q2'23
ActualEst.
-$1.94
—
Q3'23
ActualEst.
-$1.97
—
Q4'23
ActualEst.
-$0.87
—
Q1'24
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2'23
ActualEst.
—
—
Q3'23
ActualEst.
—
—
Q4'23
ActualEst.
—
—
Q1'24
Next Est.
—